AACR Presentations Highlight BATTLE Trial as New Model for Biomarker-Based Drug Studies

The BATTLE trial was the first prospective, adaptively randomized study in pretreated non-small cell lung cancer patients that mandated tumor profiling with “real time” biopsies. The 255 patients in the trial were adaptively randomized to four arms — erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib — based on their biomarker profiles.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.